The partnership combines AbTis' AbClick site-selective conjugation platform with WuXi XDC's all-in-one development and ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Astrazeneca AB has synthesized antibody-drug conjugates comprising an antibody or antigen-binding fragment covalently linked to cytotoxic moieties through enzymatically cleavable linkers reported to ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

New research shows that the combination of certain viral antibodies and genetic risk factors can be linked to a greatly ...

tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung cancer (NSCLC), typically in female individuals, who are non-smokers, and have ...